Idiopathic Dilated Cardiomyopathy: Molecular Basis and Distilling Complexity to Advance by Roura, Santiago et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Idiopathic Dilated Cardiomyopathy: Molecular Basis
and Distilling Complexity to Advance
Santiago Roura, Carolina Gálvez-Montón,
Josep Lupón and Antoni Bayes-Genis
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64996
Provisional chapter
Idiopathic Dilated Cardiomyopathy: Molecular Basis and
Distilling Complexity to Advance
Santiago Roura, Carolina Gálvez-Montón,
Josep Lupón and Antoni Bayes-Genis
Additional information is available at the end of the chapter
Abstract
Cardiomyopathies  are  heterogeneous  diseases  of  the  myocardium associated  with
abnormal findings of chamber size, wall thickness, and/or functional contractility. In
particular,  dilated  cardiomyopathy  (DCM)  is  mainly  characterized  by  ventricular
chamber enlargement with systolic dysfunction and normal left ventricular (LV) wall
thickness. Although DCM is thought to be induced mainly by genetic or environmental
factors, in the majority of cases, the cause is unknown. With an estimated prevalence of
1:2500 and an incidence of  1:18,000 per year in adults,  DCM is  the most  frequent
indication for heart transplantation, which represents an enormous cost burden on
healthcare systems. These figures warrant greater accuracy in patient diagnosis and
prognosis and further insight into the underlying basis of DCM. Here, we discuss past
and recent findings on the molecular mechanisms involved in DCM. Dilated cardio‐
myopathy has been linked to the overactivation of extracellular signal‐regulated kinase
(ERK1/2), which in turn is related to activation of low‐density lipoprotein receptor–
related protein‐1 (LRP‐1). Moreover, a redistribution of LRP‐1 into cholesterol‐enriched
plasma membrane domains (lipid rafts) and alterations in cardiac DNA methylation
have been reported in failing hearts. In conclusion, more comprehensive analyses of
myocardial lipid rafts and epigenetic mechanisms may advance our understanding of
DCM causes and progression. In turn, this understanding may promote the develop‐
ment of innovative treatments.
Keywords: dilated cardiomyopathy, heart failure, lipid rafts, LRP‐1, molecular basis,
cardiac muscle, vasculature
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1. Introduction
Cardiomyopathies are heterogeneous diseases of the myocardium associated with abnormal
findings of chamber size, wall thickness, and/or functional contractility [1]. Currently, cardio‐
myopathy is classified based on the dominant pathophysiology or by aetiological/pathogenetic
factors. This system defines four distinct categories of cardiomyopathy: dilated, hypertrophic,
restrictive, and arrhythmogenic (Figure 1) [2]. In particular, dilated cardiomyopathy (DCM) is
mainly characterized by ventricular chamber enlargement or dilatation with systolic dysfunction
and normal left ventricular (LV) wall thickness. In general, these abnormalities lead to progressive
heart failure, a decline in LV contractile function, abnormalities in ventricular and supraven‐
tricular rhythm and conduction, thromboembolism, and finally, sudden or heart failure‐related
death [3]. Indeed, DCM is a common, largely irreversible cause of myocardial damage. It is
thought to be induced by genetic or environmental factors that may manifest clinically over a
wide range of ages (most commonly in the third or fourth decade, but also in young children).
Dilated cardiomyopathy affects both sexes and all ethnic groups; it is typically identified when
patients exhibit severe limiting symptoms and incapacity [4].
Figure 1. Heterogeneous diseases of the myocardium. The different types of cardiomyopathies fall into four principal
categories, based on the muscle disorder involved. This chapter is confined to dilated cardiomyopathy.
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This chapter summarizes the most important traits (aetiology, diagnosis, treatment, and
pathophysiology) that characterize DCM. We focus on studies that provided novel insights
into the underlying molecular basis of this extremely complex human disorder. In a sense, we
will present new pieces of an intriguing puzzle, with the aim of bringing some order into the
chaos of the molecular reality.
2. Dilated cardiomyopathy: characteristic features
Dilated cardiomyopathy has an estimated prevalence of 1:2500, an incidence of 1:15,000–18,000
per year in adults, and an estimated prevalence of 2:3 among children with unknown diseases
[4, 5]. The clinical course of DCM can be progressive; one study reported that about 35% of
individuals died within 5 years after diagnosis [1]. The origin of death is divided evenly
between sudden death and pump failure. To date, prolonged survival has been achieved with
neurohormone blockers (angiotensin-converting enzyme inhibitors and β-adrenoceptor
antagonists) and devices (cardiac resynchronization and implanted defibrillators). Neverthe-
less, the only definitive treatment is heart transplantation, which is hampered in many
instances by the limited number of heart donors and by graft rejection over time. Therefore,
DCM is the most frequent indication for heart transplantation, which results in an enormous
cost burden for healthcare systems throughout the world. Diagnosis is typically based on
patient history and the presence of LV dilatation and impaired ejection fraction, with or
without regurgitation; these signs are detected with echocardiography, cardiac magnetic
resonance imaging, or both.
At the histological level, the main pathological derangements observed in explanted diseased
hearts are patchy interstitial fibrosis surrounding myocardial filaments, marked lipid deposi-
tion, cardiac muscle atrophy, and lipid accumulation [6–8]. Moreover, further investigations
of both patient samples and animal disease models have shown that DCM hearts exhibit
marked vascular alterations [9, 10]. In most cases, the causal mechanism of disease is poorly
understood. This reality has induced some authors to argue that heart disease in DCM arises
from an obscure origin, and this viewpoint has given rise to the term ‘idiopathic’ DCM.
Recently, relevant advances have been made in our understanding of the causes of this disease.
The main causes include familial and genetic disorders, infectious and toxicity-related
processes, autoimmunity, and inflammation [4].
Frequently, DCM has been defined as the result of an extremely complex genetic architecture
that involves disruptions in a variety of myocardial proteins, which are provoked by rare
variants in some genes; moreover, many of these genes are also involved in other cardiomyo-
pathies, such as muscular dystrophy or syndromic diseases [11]. In brief, numerous DCM-
associated genes have been identified. This information has provided a better understanding
of disease pathogenesis, and it has promoted advances in mutation analytical techniques to
facilitate the recognition of subjects and progeny that carry these mutations [12]. Alterations
in more than 50 loci and genes have been identified, which mostly encode either cardiac
myocyte-specific proteins or structural, nuclear membrane, and calcium metabolism proteins.
Idiopathic Dilated Cardiomyopathy: Molecular Basis and Distilling Complexity to Advance
http://dx.doi.org/10.5772/64996
103
However, it is estimated that genetic disorders account for only 20–35% of DCM cases [12,
13]. Some researchers have predicted that genetic associations may have been missed due to
the limited nature of previous studies; accordingly, they point to a need for more comprehen‐
sive studies in much larger cohorts of families that are rigorously phenotyped [11]. In addition,
some cases of DCM are believed to be related to autoimmune and inflammatory processes [14–
16]; metabolic, nutritional, and endocrine deficiencies; or heart muscle damage following
exposure to viruses, exogenous drugs, or toxins (e.g., chronic alcohol consumption) [2].
Peripartum cardiomyopathy also represents a subset of LV systolic dysfunction. In the latter
cases, initial symptoms of heart failure occur during the late stages of pregnancy [17]. Although
there may be a variety of causes for DCM, the clinical presentation of this disease seems to be
uniform, both in humans and in animal models that have been used to dissect DCM develop‐
ment, progression, and treatment [10].
Standard treatment of DCM involves neurohormonal inhibition of the renin‐angiotensin‐
aldosterone system (i.e., angiotensin‐converting enzyme inhibitors, angiotensin II receptor
type 1 blockers, or mineralocorticoid receptor blockers) or blocking the sympathetic nervous
system with β‐blockers. In patients, it is crucial to focus on improving cardiac function and
reducing mechanical stress. Although progress has been made in arrhythmia therapy and in
sudden death prevention, many impediments for improving patient outcomes remain
unresolved [4]. Innovative therapies, such as stem cell‐based applications, are also being
investigated [18].
3. Dilated cardiomyopathy affects both cardiac muscle and the vasculature
Dilated cardiomyopathy is associated with pronounced remodelling of one or both ventricles,
which results in large changes in the shapes of ventricles and in the architecture of myocardial
fibres. As mentioned previously, the main microscopic hallmarks of failing hearts are marked
collagen deposition, patchy interstitial fibrosis, degenerated cardiac muscle cells, and sparse
blood vessels. At the ultrastructural level, remodelling comprises mitochondrial abnormali‐
ties, T‐tubular dilatation, and intracellular lipid droplet accumulation [10]. Because the
mitochondrion is the main site of ATP production and cardiac myocytes are particularly
sensitive to the supply of energy, deficits in mitochondrial function have been linked to DCM
[19]. Additionally, altered levels of connexin‐43 and modulation of its phosphorylation state
can induce electromechanical uncoupling between neighbouring cardiac muscle cells [20].
A number of studies have indicated that programmed cell death or apoptosis contributes
actively to human end‐stage heart failure. Indeed, cell death occurs in myocardial ischemia‐
reperfusion [21], ischemia‐reperfusion injury [22], and fatal myocarditis [23]. However, the
role of apoptosis in the DCM myocardium remains controversial, due to some limitations in
the techniques that have been used to measure apoptosis [24–26]. A positive Terminal deoxy‐
nucleotidyl transferase dUTP nick end labeling (TUNEL) signal seems to require fragmenta‐
tion of only 10% of all DNA; as a result, the level of apoptosis may be highly overestimated [24].
Furthermore, cells that are apoptotic, necrotic, undergoing DNA repair, or living can emit
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equivalent signals in the TUNEL assay [27], which renders the use of this method even more
questionable. Consequently, although some authors have reported putative increases in
apoptotic markers with different methodologies, including caspase‐3 activity, DNA fragmen‐
tation (TUNEL), and electron microscopy [28], others have failed to detect changes in apop‐
tosis. For instance, Bott‐Flügel et al. did not detect any correlations between caspase‐3 activity,
the induction of DNA fragmentation, and haemodynamic or echocardiographic variables in
patients with end‐stage heart failure, including DCM. Moreover, they did not find significant
differences in caspase‐3 activation between DCM and control myocardium [26]. Figure 2 shows
that only slight amounts of caspase‐3 mRNA and protein were detected in LV samples from
patients (unpublished results). These findings suggest that cardiac muscle cells might trigger
apoptotic self‐destruction, without completing the process. Hence, DCM is characterized by
marked abnormalities in the function and integrity of cardiac muscle.
Figure 2. Comparative analysis of apoptosis in left ventricle samples collected from human explanted DCM hearts and
control hearts from non‐cardiac decedents. Representative caspase‐3 gene (A) and protein (B) expression levels by
quantitative RT‐PCR and Western blotting, respectively.
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Cardiac endothelial dysfunction was also associated with disease progression and a poor
prognosis in patients with DCM. In the late 1940s, preliminary observations showed a
correlation between heart weight and the total cross‐sectional size of the main coronary
vessels [29]. Since then, a number of studies have recognized that cardiac vasculature is a key
regulator of the integrity and function of the myocardium. In an attempt to take this a step
further, Brutsaert et al. studied the mechanical properties of the mammalian ventricular
myocardium before and after damaging the endocardial surface [30]. Those authors speculated
that the endocardium could affect myocardial performance by either forming an electrochem‐
ical barrier, releasing a chemical substance or messenger, or both. They subsequently demon‐
strated that nitric oxide synthase activity regulated the contractile responsiveness of
ventricular myocytes [31]. Perhaps more significantly, additional studies in Langendorff‐
perfused and post‐infarcted rat hearts confirmed that endothelial damage led to progressive
myocardial dysfunction and that, conversely, protecting the associated vasculature preserved
global myocardial homeostasis [32, 33].
Figure 3. Foundation of DCM as a two‐hit heart disease. The integrity and function of both cardiac muscle and vascu‐
lature are adversely compromised in DCM, which leads to LV remodelling and pump failure.
Advances in medical imaging techniques have become crucial for performing more compre‐
hensive analyses of vascular derangements in DCM. Angiography revealed that a mismatch
between artery size and LV mass in patients with DCM contributed to myocardial hypoper‐
fusion [34–37]. Computed tomography measurements of DCM cardiac vasculature on a
multislice scanner have also clearly shown side branch paucity and shortened, thinned
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epicardial arteries [9]. Therefore, the epicardial coronary arteries in patients with DCM are not
adequately sized for the enlarged LV mass. Notably, a variety of studies described significantly
reduced, sparse microvasculature in diseased myocardium samples [9, 38, 39]. In this context,
numerous studies in patients with DCM have reported that the circulating levels of distinct
bone marrow‐derived cell populations are peripherally increased after vascular damage [40].
Although there is a correlation between the circulating levels of these progenitor cells and the
progression and clinical outcomes of DCM, the clinical usefulness of this overrepresentation
awaits further validation.
Collectively, these findings led to a re‐examination of the pathophysiology of DCM. In 2009,
Roura and Bayes‐Genis [10] reviewed the extensive data from animal models and patients and
concluded that DCM is a two‐hit disease, where both cardiac muscle and endothelial altera‐
tions contribute equally to contractile deficiency and pump failure (Figure 3).
4. Molecular basis of dilated cardiomyopathy: past and new actors
Molecularly, in humans, DCM has been related to intramyocardial accumulation of α‐2
macroglobulin (α‐2M) [41] and increased activation of extracellular signal‐regulated kinase
(ERK1/2) [42]. In a mouse model of DCM, the disease was generated by a mutation in the lamin
A/C gene [43, 44]. In these mice, chemically suppressing ERK1/2 activation prevented LV
dilatation and greatly restored the cardiac ejection fraction.
The α‐2M protein is a highly abundant plasma protease inhibitor, which has been shown to
activate various tyrosine kinases and mitogen‐activated protein kinases [45]. Moreover, α‐2M
was one of the first molecules to be described as a ligand of low‐density lipoprotein (LDL)
receptor‐related protein 1 (LRP‐1) [46]. A recent review described LRP‐1 as a multifunctional
receptor of the LDL‐receptor family that mediates the clearance of a variety of structurally
diverse extracellular molecules [47]. Moreover, LRP‐1 plays key roles in various biological
processes by interacting with multiple intracellular signalling pathways [48, 49]. As a result,
LRP‐1 tyrosine phosphorylation can be activated in response to diverse extracellular mole‐
cules, such as platelet‐derived growth factor [50–52]. In particular, ERK1/2 activation is
recognized as one of the main LRP‐1 molecular relays [53–55]. In the following pages, we
present and discuss novel data demonstrating that, together with the pivotal role of LRP‐1 in
the vascular wall and in the aetiology of atherosclerosis [56], LRP‐1 is redistributed and
overactivated within some specialized plasma membrane domains, termed lipid rafts, in DCM
myocardium.
The decreased capillary density found in patients with DCM was shown to arise from
impairments in myocardial endothelial cell survival and insufficient revascularization. These
processes involve several intracellular signalling pathways, including those mediated by
vascular endothelial (VE)‐cadherin/β‐catenin, angiopoietins, and vascular endothelial growth
factors (VEGFs). In particular, VE‐cadherin, β‐catenin, angiopoietin‐2, VEGF‐A, VEGF‐B, and
VEGF receptor‐1 (VEGFR‐1) expression levels were downregulated in DCM [9, 57, 58]. Roura
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et al. [9] further demonstrated that reduced expression of β‐catenin, an important angiogenic
regulator [59], occurred exclusively in myocardial vascular cells in failing hearts.
Remarkably, different DNA methylation patterns have been detected in genes that regulate
pathways related to heart disease and in genes with unknown functions in DCM. For example,
variations in DNA methylation were observed in lymphocyte antigen 75, tyrosine kinase‐type
cell surface receptor HER3, homeobox B13, and adenosine receptor A2A [60]. These validated
targets are most likely involved in modifying DCM rather than independently causing disease.
Furthermore, other authors found differentially methylated gene promoters and a depletion
of mitochondrial DNA that resulted in a thymidine kinase deficiency in DCM hearts [61, 62].
Indeed, investigating epigenetic mechanisms represents an attractive approach for finding
novel mechanisms of disease.
Figure 4. Potential impact of lipid raft–associated signalling on DCM. Schematic illustration of a lipid raft domain in a
portion of the cell surface. Proteins potentially involved in disease progression are either packed into or excluded from
these specialized plasma membrane areas.
For more than 40 years, the Singer and Nicolson model of the cell membrane, where proteins
are viewed as icebergs floating in a sea of lipids, has provided a solid foundation for studying
cell membrane properties [63]. This enduring model was subsequently reinterpreted with the
discovery of localized, highly cholesterol‐ and glycosphingolipid‐enriched plasma membrane
areas, referred to as ‘lipid rafts’ [64]. Many proteins, particularly those involved in cell
signalling and cytokine presentation, were found to be densely packed together in these
specialized surface domains [65]. Accordingly, lipid rafts facilitate interactions between protein
receptors and mediators by maintaining them tightly packed together in one location.
Interestingly, LRP‐1 was reported to be associated with lipid rafts [66, 67].
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As previously mentioned, recent research has given us new molecular aspects of the disease.
Particularly, in patients with DCM, LRP‐1 was seen redistributed and further activated,
through tyrosine phosphorylation, within lipid rafts enriched in caveolin‐3 and flotillin‐1 [68].
Of note, these observations suggested that movement of LRP‐1 within these specialized
membrane domains contribute to the overactivation of ERK1/2‐mediated signalling described
in DCM. However, further confirmatory exploration is warranted to determine whether this
overactive signalling leads to the characteristic promotion of extracellular matrix metallopro‐
teinase activity and subsequent LV remodelling (Figure 4) [69, 70].
To investigate this novel regulatory impact of lipid rafts on DCM, Roura et al. extracted lipid
rafts from failing myocardium and detected elevated amounts of the mobilizing cytokine,
stromal cell‐derived factor (SDF)‐1 [71]. In that same study, the authors showed that deficien‐
cies in ILK and ERK1/2 signalling impeded SDF‐1‐mediated migration of circulating progen‐
itor cells. As a result, impaired cell migration compromised endothelial maintenance and
recovery, which contributed to the marked vascular derangements observed in diseased
myocardium [72].
Taken together, these observations support the growing body of data that led to the recognition
of myocardial lipid rafts and their associated proteins as modulators of cardiac performance
and as novel therapeutic targets [73–75].
5. Conclusions
Heart failure has become an increasingly common disorder worldwide, and it is associated
with substantial morbidity and mortality. Many causes of heart failure are easily identified in
clinical practice, including abnormal heart valves, inherited cardiomyopathies, severe coro‐
nary artery disease, or hypertensive heart disease. However, the precise mechanisms that
govern the progression of heart failure and ventricular remodelling in DCM remain obscure.
Some authors have appropriately pointed out that, for both clinicians and researchers,
attempting to discover the underlying genetic and environmental causes linked to complex
human diseases, such as DCM, is like facing a drawer filled with thousands of puzzle pieces
mixed together from an unknown number of jigsaw puzzles [76, 77]. The question remains,
how can they begin to solve it?
There is a growing body of data that describes the multifaceted genetic diversity involved in
DCM and the alterations in both cardiac muscle and vasculature that contribute to the disease.
However, several crucial issues remain to be addressed. For example, it is not clear whether
the marked vascular deficiencies observed in patients with DCM develop secondary to heart
remodelling, or whether they directly contribute to myocardial alterations and to the temporal
evolution of LV dilatation. Accordingly, researchers are providing novel mechanistic insights
that might bring some order to this ‘disordered’ collection of data. For example, they have
shown that lipid rafts participate in the mechanism underlying the spatial regulation of LRP‐1‐
mediated ERK1/2 activity. Undoubtedly, further work is needed to increase our comprehension
of the causes underlying this ‘obscure’ disease. To that end, the current state of knowledge
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summarized in the present review provides a starting point for addressing the remaining
questions in the pathophysiology of this disease. Moreover, we highlight new avenues for
discovering potentially effective treatments.
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